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What is already known about this subject  
 Faecal immunochemical tests (FIT)  for haemoglobin (Hb) have been recommended as the 
preferred method for population colorectal cancer screening 
 Several different FIT have been introduced and standardisation on faecal Hb concentration 
has been recommended for comparison.  
 Available comparative information about diagnostic performance of different methods are 
mainly derived through laboratory-based studies.   
 
What are the new findings 
 The acceptability and the diagnostic performance of two FIT systems (OC-Sensor and HM-
JACKarc)  are similar in a screening setting. 
 Diagnostic performance of FIT systems may be influenced by subject’s screening history 
(i.e., expected prevalence of the disease). 
 Setting the faecal Hb cut-off to achieve the same positivity rate with the two systems 
resulted in the same advanced neoplasia yield and positive predictive value,  
 
How might it impact on clinical practice in the foreseeable future? 
 Adopting faecal Hb concentration cut-offs to give equivalent positivity rates, thus using the 
same endoscopy resources, allows for a direct comparison of the performance of different 
FIT.  This strategy might reduce the variability related to the individual FIT methodology, 
since this could alter the relationship between Hb concentration and positivity rate.  
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ABSTRACT  
Aim: To compare acceptability and diagnostic accuracy of a recently available faecal 
immunochemical test (FIT) system (HM-JACKarc, Kyowa Medex Co., Ltd) with the FIT routinely 
used in an established screening programme (OC-Sensor, Eiken Chemical Co., Ltd).  
Design: Randomised controlled trial (ISRCTN20086618) within a population-based colorectal 
cancer (CRC) screening programme. Subjects eligible for invitation in the Umbria Region (Italy) 
programme were randomised (ratio 1:1) to be screened using one of the FIT systems.  
Results: Screening uptake among the 48,888 invitees was the same for both systems among 
subjects invited in the first round and higher with OC-Sensor than with HM-JACKarc (RR: 1.03; 
95%CI: 1.02-1.04) among those invited in subsequent rounds. Positivity rate (PR) was similar with 
OC-Sensor (6.5%) as with HM-JACKarc (6.2%) among subjects performing their first FIT 
screening and higher with OC-Sensor (5.6%, RR: 1.25, 95%CI: 1.12-1.40) than with HM-JACKarc 
(4.4%) among those screened in previous rounds. Positive predictive value (PPV) (OC-Sensor: 
25.9%, HM-JACKarc: 25.6%) and detection rate (DR) (OC-Sensor: 1.40%; HM-JACKarc: 1.42%) 
for advanced neoplasia (AN: CRC + advanced adenoma) were similar among subjects performing 
their first FIT screening. The differences in the AN PPV (OC-Sensor: 20.3%, HM-JACKarc: 
22.6%) and DR (OC-Sensor: 0.96%, HM-JACKarc: 0.83%) among those screened in previous 
rounds were not statistically significant. The number needed to scope to detect one AN was 3.9 
(95%CI: 5.8-2.9) and 3.9 (95%CI: 5.5-2.9) at first and 4.9 (95%CI: 5.8-4.2) and 4.4 (95%CI: 5.3-
3.7) at subsequent screening, with OC-Sensor and HM-JACKarc respectively. 
Conclusion: Our results suggest that acceptability and diagnostic performance of HM-JACKarc 
and of OC-Sensor systems are similar in a screening setting. 
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INTRODUCTION 
Following the recommendation for Europe to adopt faecal immunochemical tests (FIT) for 
haemoglobin (Hb) as the initial non-invasive investigation of choice for population-based colorectal 
cancer (CRC) screening programmes1, several different qualitative and quantitative FIT have 
become available for use in both screening and clinical settings.  While the availability of several 
tests may stimulate competition, lower costs and promote technical improvements, data concerning 
the diagnostic performance of FIT are still mainly derived from laboratory-based evaluations2-3, 
from studies conducted in clinical settings4-6, or from studies using a paired design7-9. The 
availability of reliable information about the performance of new FIT in screening settings is 
crucial, however, since even relatively small variations in performance characteristics can have  
substantial impacts on programme organisation and delivery.  
 
The positivity rate (PR) that personnel and financial resources can accommodate varies across 
regions and limited endoscopy capacity has been identified as a barrier to initiation and expansion 
of screening in several settings10-11. An increase in the number of colonoscopies resulting from a 
higher PR could lead, for example, to longer waiting times for assessment of participants with 
positive test results and this could eventually lead to in a reduction in the population invited for 
screening. Similarly, a reduction in the positive predictive value (PPV) can negatively affect the 
cost-benefit balance of a programme. Moreover, practical aspects, for example, the design and ease 
of use of the sample collection device can play a role when the selected population is invited to 
participate2,11. The device should be designed such that inadequate sampling or leakage are 
minimised. It should be easy to label with adequate information to identify the sample and it should 
also be suitable for packing and dispatch by normal post. The users’ preferences for different 
devices need therefore to be assessed. Finally the costs of the system and of the postage, when 
relevant, need to be assessed as well 11. 
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Comparative effectiveness studies, conducted in the context of established CRC screening 
programmes, as performed in a recent study from The Netherlands,12 may therefore represent a 
valuable methodology to gather the information relevant to assist screening planning and decision-
making about the adoption of screening tests. We conducted a randomised controlled trial (RCT) 
within a population-based CRC screening programme to compare the acceptability and the 
diagnostic accuracy the FIT routinely used in a well-established programme (OC-Sensor, Eiken 
Chemical Co., Ltd, Tokyo, Japan) with  a recently available automated quantitative FIT system 
(HM-JACKarc, Kyowa Medex Co., Ltd, Tokyo, Japan).   
 
METHODS 
The Umbria Region CRC screening programme.  An organised population-based CRC 
screening programme was started in the Umbria Region (Italy) in 2006. All residents aged 50 to 74 
years are targeted for invitation biennially and asked to collect a single faecal sample for subsequent 
analysis by FIT. The FIT sample collection device is mailed to the potential participants, together 
with a personal invitation letter signed by the appropriate general practitioner (GP), an information 
leaflet, the instructions for collecting and storing the sample and a pre-paid envelope for returning 
the device. Each device is identified by the participant’s name and social security number in bar-
code format. The handling of the devices, as well as the test results, is fully automated: participant’s 
data are entered in the screening data-base using a bar-code reader by the laboratory staff when the 
device is processed and the results of the analytical determination of the faecal haemoglobin 
concentration (f-Hb) are directly recorded in the same data-base, linked to the analytical system.  
Subjects with a positive test result are invited by mail for a colonoscopy in one of five reference 
endoscopy centres, which reserve dedicated sessions for participants in the programme. The entire 
screening process, and treatment when necessary, are offered free of charge, following the quality 
standards recommended by national13 and EU guidelines1. An automated linkage between the 
screening and pathology data-bases supports timely and comprehensive recording of all 
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colonoscopy and treatment results for each participant with a positive test result.  
Randomization and invitation. We designed a randomized controlled trial (ISRCTN20086618) 
within our regional programme; the study was approved by the local Ethics Review Board (Prot. 
n.3032/14/AV 29/04/2014).  Subjects eligible for invitation during the enrolment period (from 06 
November 2014 to 31 March 2015), were randomly allocated (ratio 1:1) to be screened with one of 
the two FIT systems, namely, OC-Sensor and HM-JACKarc. The randomisation was stratified by 
gender, age group (five five-year age groups between 50 and 74 years of age), screening history 
(first and subsequent screening) and area of residence (urban and rural). The scheme was computer 
generated within the screening programme IT system and identified when individuals were to be 
invited to participate. The process of generating and mailing the different invitation materials was 
fully automated, therefore blinding the researchers to the allocation of the intervention to 
individuals.  
Following the standard screening protocol, potential participants with a previous diagnosis of CRC 
(information derived from the hospital discharge records data-base), those having performed a FIT 
within the previous two years, or those who had a colonoscopy within the previous five years 
(identified from information available from the regional screening and endoscopy data-bases) and 
those suffering from terminal illness, or unable to provide informed consent (GP indication), were 
excluded from the invitation. A reminder letter was mailed to all non-responders three months 
following the initial invitation. The invitation kit mailed for the study included an informed consent 
form and a leaflet explaining the design and the rationale for the study. The invitation, containing 
pictorial and written materials, were designed to be as similar as possible for each of the analytical 
systems. 
Participants were instructed to store the completed device at 4°C and to send it back to the central 
laboratory as soon as possible. Devices were collected and forwarded to the screening laboratory 
every day by the postal company, following the routine procedures of the screening programme. 
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Laboratory and quality control procedures.  Following the Faecal Immunochemical Tests 
Evaluation Reporting (FITTER) guidelines, f-Hb results were reported as µg Hb/g faeces, as 
recommended by the Expert Working Group on FIT for Screening, the Colorectal Cancer Screening 
Committee, World Endoscopy Organization14. All analyses were performed in the central laboratory 
of the Umbria screening programme (National accreditation: CERMET  ISO  9000:2000, ISO 
9001:2008, ISO 9004:2000, UNI EN 19011:2003; D.D. n. 9628 del 21/11/2014) by three 
experienced laboratory medicine professionals. A detailed description of the calibration procedures 
and the observed analytical coefficients of variation (CV) for the two systems is available in 
supplement 1 (online). 
The OC-Sensor device collects 10 mg faeces with a serrated probe attached to the cap into 2.0 ml 
buffer2. The cap is pushed on to the device which incorporates a small filter that removes faecal 
particulate matter from the sample in buffer before analysis, a feature that reduces the possibility of 
incorrect sampling.  The analytical working range is 10-200 µg Hb/g faeces. Dilution is semi-
automated after manual identification of samples with f-Hb higher than the upper analytical limit 
and manual replacement of the sample tube on the analyser. This dilution extends the analytical 
range beyond the undiluted upper analytical limit of 500 μg Hb/g faeces2. The HM-JACKarc device 
collects 2 mg of faecal material in dimples in the probe attached to the cap of the device into 2.0 ml 
buffer; the cap is screwed onto the sampling device. The analytical working range is 7-400 µg Hb/g 
faeces: the system has no automated system for automatic dilution and re-analysis of samples that 
have a f-Hb higher than the upper analytical limit2. 
Faecal samples were stored at 4°C in the laboratory until the time of the analysis, which was usually 
performed on the day of receipt and no later than the following day. An identical f-Hb cut-off 
criterion for referral for colonoscopy (20 µg Hb/g faeces) was used for both systems. The f-Hb 
results were recorded electronically and were automatically linked to the participant’s record in the 
screening data-base. 
Colonoscopy. Colonoscopy was performed in five regional reference centres using standard high-
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definition endoscopes following a cathartic bowel preparation. The examination was considered 
complete if the caecum was visualized or, in the case of failure, when a subsequent colonoscopy, 
performed within the following six months, reached the caecum; the combined results of the two 
examinations were considered for analysis. All detected lesions were measured with open biopsy 
forceps and annotated according to size, morphology and localization. Histology was defined 
according to the World Health Organization criteria15: advanced adenoma (AA) was defined as an 
adenoma with any of the following features: size ≥10 mm, high-grade dysplasia, or villous 
component >20%; cancer was defined as the invasion of malignant cells beyond the muscularis 
mucosae. 
Statistical analysis. The performance indicators considered in our comparative analysis included 
proportion of inadequate tests, positivity rate (PR), PPV, detection rate (DR) for CRC and AA, 
number needed to scope (NNScope) to detect one advanced neoplasm (AN = CRC+AA). We also 
compared the participation rate with the two methods, although there was no reason to expect major 
differences in uptake given that the two systems do not show substantial differences when 
characteristics such as the design and handling of the specimen collection devices possibly affecting 
their acceptability are considered.  However, it might be that  that offering a new device, albeit only 
slightly different from that promoted in the mass-media campaigns encouraging participation, might 
have some impact on the uptake. 
Sample size was determined based on the expected participation rate (50%), PR (5%) and AN DR 
(1%), derived from the observed results of our screening programme. Based on these assumptions, 
enrolling 25,000 participants for each analytical system would allow  detection of a 1.0%, 0.4% and 
7.0%  absolute difference between the two systems in positivity, AN DR and PPV, respectively, as 
statistically significant (α: 0.05; power: 80%).  The exact method was used to calculate the 95% 
confidence intervals (CI) of proportions; 95% CI for the NNScope were calculate as the inverse of 
the 95% CI of the corresponding PPV. Relative risk (RR) with 95% CI was used as a measure of 
association the outcomes of interest between analytical systems, setting the OC-Sensor as the 
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reference system.  The standardised estimates were compared using a direct standardisation method 
assuming the total population included in the study as the reference for calculations. All statistical 
tests were two-sided and a p-value of less than 0.05 was considered statistically significant. 
 
RESULTS 
 
During the recruitment period, 48,888 people (22,840 men and 26,048 women) were invited: 
47.2% of them were living in urban areas (>150 subjects/km2) and 52.8% in rural areas. The 
participation was 57.4% in the former and 63.2% in the latter. Out of the 48,888 invitees, 24,314 
(11,319 men and 12,995 women) were randomised to the OC-Sensor group and 24,574 (11,521 men 
and 13,053 women) to the HM-JACKarc group. The two groups were comparable in age, gender 
and screening history (Table 1). 
Participation (Table 2) was the same for both systems among individuals invited for the first 
time in the programme (first screening round), while it was slightly higher with OC-Sensor than 
with HM-JACKarc (RR: 1.03; 95%CI: 1.02-1.04) for those who had already been invited in 
previous rounds in the programme (subsequent screening rounds). A similar trend toward a lower 
participation among men than among women invited in the first screening round was observed both 
with OC-Sensor (RR: 0.80 (95%CI: 0.73-0.88) and with HM-JACKarc (RR: 0.83 (95%CI: 0.76-
0.92); an opposite trend was observed among people having already participated in previous rounds, 
showing a higher participation among men than among women (OC-Sensor - RR: 1.04 (95%CI: 
1.02-1.05).;  HM-JACKarc - RR: 1.02 (95%CI: 1.01-1.04). Participation was higher in the youngest 
age group (50-54 years) for both systems at first screening and among people age 60 to 69 years as 
compared to younger or older age groups at subsequent screening rounds. 
The overall PR (Table 3) was 6.4% (271/4247) at first and 5.0% (1240/24751) at subsequent 
screening and, as expected, it was higher among men than among women and increased with age 
quintile. Positivity was similar with OC-Sensor (6.5%) as with HM-JACKarc (6.2%, RR: 1.05, 
95%CI: 0.84-1.33) at first screening, while it was higher with OC-Sensor (5.6%, RR: 1.25, 95%CI: 
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1.12-1.40) than with HM-JACKarc (4.4%) at subsequent screening, with a similar trend among men 
and women.  
The uptake of colonoscopy in those with positive test results was the same (Table 3) with OC-
Sensor (overall: 84.1%, men: 85.7 %, women: 82.5%) as with HM-JACKarc (overall: 83.8%, men: 
83.3%, women: 84.3%), as was the completion rate of the examinations. Out of 672 subjects who 
undertook an assessment colonoscopy in the OC-Sensor group, 29 (4.1%) repeated the investigation 
within six months, following an incomplete index colonoscopy (N = 12), or to check completeness 
of polypectomy; similarly, in the HM-Jackarc group, 15 out of 553 (2.6%; p=0.166) repeated the 
investigation within six months (two following inadequate preparation and 12 to assess the site of 
polypectomy).     
PPV for AN was similar for the two systems (OC-Sensor: 25.9%, HM-JACKarc: 25.6%) at 
first screening (Table 4) as it was also for the AN DR (OC-Sensor: 1.40%; HM-JACKarc: 1.42%).  
However, the PPV for AN at subsequent screening of a positive test result was lower with OC-
Sensor (20.3%; 95%CI: 17.4%-24.1%) than with HM-JACKarc (22.6%, 95%CI: 18.9%-26.8%), 
but the difference did not reach the level of statistical significance. The AN DR was slightly higher, 
but not statistically significant, with OC-Sensor (0.96%) than with HM-JACKarc (0.83%). The 
NNScope to detect one case of AN was 3.9 (95%CI: 5.8-2.9) and 3.9 (95%CI: 5.5-2.9) at first 
screening with OC-Sensor and HM-JACKarc respectively; the corresponding figures at subsequent 
screening were 4.9 (95%CI: 5.8-4.2) and 4.4 (95%CI: 5.3-3.7).   
Staging was available for all CRC detected at first screening both with OC-Sensor (N = 5; 
UICC stage: I = 4; II = 1) and with HM-JACKarc  (N = 5; UICC stage: I = 2; II = 1; III = 2); 
staging information for CRC detected at subsequent screening was available for 11 (UICC stage: I = 
7; II = 1; III = 3) out of 14 cases detected with OC-Sensor and for 15 (UICC stage: I = 9; II = 1; III 
= 5) out of 16 cases  detected with HM-JACKarc.The proportion of CRC located in the proximal (to 
the descending colon) segments was 26.3% and 27.8% with OC-Sensor and HM-JACKarc 
respectively; the corresponding data for AN were 41.9% and 33.0%. Neither difference reached 
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statistical significance. 
The results remained the same when considering standardised comparisons (data not 
shown): the PR was slightly different among participants at the initial screening test (OC-Sensor: 
6.3% and HM-JACKarc: 6.6%) but the difference was not statistically significant; the crude and 
standardised estimates for PR, PPV and DR were the same when considering participants in 
subsequent screening rounds.  
After increasing the f-Hb cut-off criterion for PR of OC-Sensor at subsequent screening (from 20 to 
29 µg Hb/g faeces) to achieve the same PR as observed with HM-JACKarc (data not shown), the 
difference in the AN yield between the two methods was substantially reduced (OC Sensor: PPV: 
21.0%; DR: 0.78%; NNScope: 4.8). 
 
DISCUSSION 
 In a randomised controlled trial undertaken in the context of a population-based CRC 
screening programme, OC-Sensor and HM-JACKarc  FIT analytical systems showed  similar 
participation patterns by gender, age and screening history. The observed 3.0% increase in the 
participation rate with OC-Sensor among individuals having already participated in previous rounds 
may be related to the initial impact of a new and slightly different specimen collection device. Since 
all invitation kits were sent by post, following the well established procedures of the programme, 
individuals already used to performing the faecal sampling with the previous device might have 
faced difficulties in understanding the reasons for change, possibly enhancing negative attitudes to 
the experimental context. Importantly, those invited for their first time in the programme showed 
the same response with both systems, which would support this hypothesis. The lower participation 
found among men when compared to women across all age groups, as well as the trends for age and 
screening history are consistent with the results in Italian screening programmes 16. 
PR, PPV and AN DR among participants undertaking their first screening were similar, 
while a higher PR among people with previous negative test results was observed when using the 
OC-Sensor as compared to the HM-JACKarc. Since the majority of participants screened after 
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completion of the roll-out phase of a screening programme are expected to have already taken part 
in previous rounds (about 85% in the current programme), the reduction in the PR in this group will 
have a favourable impact on the endoscopy workload of a population based programme. The PPV 
for AN was also slightly decreased with OC-Sensor as compared to the HM-JACKarc, when 
considering subjects with previous negative test results, but the difference did not reach statistical 
significance, since the DR was similar for CRC, but slightly higher for AA with the OC-Sensor than 
with HM-JACKarc. Although the observed increase was not statistically significant, it must be 
realised that our study was powered to detect larger differences. Assuming that the observed 
increase could be declared statistically significant in a larger sample, it can be estimated that about 
eight additional colonoscopies would be necessary to detect one additional AN over 1,000 
participants with OC-Sensor. Whether such an increase in the colonoscopy workload to achieve this 
small increase in the DR would be acceptable and sustainable can likely be determined only for 
each programme individually. Availability of such information can, however, inform a more 
explicit decision-making process.  
Following the proposal to standardize the measuring units of f-Hb to µg Hb/g faeces,14 to 
take into account the different masses of faeces collected and the volumes of the buffer in the 
devices, identical f-Hb cut-offs were adopted in for both systems. While similar PR and PPV were 
observed when using the same f-Hb cut-off among participants performing their first screening test, 
harmonisation of f-Hb cut-off did not result in similar PR with the two systems among subjects 
However, setting a higher f-Hb cut-off criterion for the PR with the OC-Sensor at subsequent 
rounds, to achieve the same PR with the two systems (29 µg Hb/g faeces rather than 20 µg Hb/g 
faeces) would result in a similar diagnostic performance. Grobbee et al.12 have pointed out recently 
that comparison between FIT systems is usually done at the same f-Hb. Our findings support their 
thesis that improved comparison on diagnostic yield would be achieved with PR rather than f-Hb.  
A future publication will explore, in detail, a comparative analysis of f-Hb with the two systems, 
stratified by age, gender, screening history and type of lesions to test this hypothesis.  The reasons 
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for the observed difference in the PR between the two systems at subsequent but not at first round, 
when using the same standardised f-Hb cut-off need to be investigated. The lower prevalence of 
neoplasia among people with previous negative results  might result in lower average f-Hb and, for 
a number of reasons,12 different methods might show  different performances. 
The site distribution of the screen detected lesions observed is consistent with previous 
reports, reflecting both the expected distribution of CRC and adenoma across colonic site, given the 
age distribution of our population 17 and the documented higher sensitivity of FIT for distal 
lesions18 . 
Conflicting data have been reported from previous studies comparing OC-Sensor and HM-
JACKarc systems. In a recent Italian study 19 inviting 5044 subjects to receive both OC-Sensor and 
HM-JACKarc devices, after f-Hb cut-off optimisation, OC-Sensor showed a lower PR (3.5% v 
6.2%) and a lower relative sensitivity for AN (73.7 v 88.2%) than HM-JACKarc. The specificity 
was 97.6% for the OC-Sensor and 96.0% for the HM-JACK, resulting in a decrease of the required 
assessments from 5.1 to 3.5% and in an estimated 30% decrease of the costs for every individual 
investigated for AN. On the other hand, a study comparing two cohorts screened either with OC-
Sensor or HM-JACK (using the same 20 µg Hb/g faeces cut-off for positivity), in the context of a 
screening programme in Taiwan 20, showed a similar PR and DR for AA for both systems but a 
lower CRC DR and a lower interval cancer rate with OC-Sensor than with HM-JACK: however, the 
HM-JACK is not an identical system to the HM-JACKarc evaluated in our study. Moreover, 
differences in the screened populations (including baseline prevalence of disease, characteristics of 
the screened population with respect to gender, age and screening history) as well as in the f-Hb 
cut-off criteria for positivity, may explain the observed findings in the Taiwan study 18. These 
studies do suggest that, even when using a standardized reporting unit system, identical f-Hb may 
perform differently between systems, while the choice of a suitable  f-Hb cut-off for positivity in a 
population-based screening setting should take into account also the PR, influencing the 
colonoscopy workload.  Our results, showing a similar diagnostic performance of the two systems, 
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may not be directly comparable with the findings from previous reports, since updated systems 
were used both for OC Sensor (different buffer) and for HM-JACKarc (different analytical system, 
collection device and analytical range to the HM-JACK system). They would support, however, the 
conclusion of the Taiwan study suggesting that differences in diagnostic performance may still be 
expected, despite harmonisation of f-Hb cut-off.  
One of the main strengths of our study is that it was conducted in standard care conditions, 
within an established population-based CRC screening programme, targeting both men and women 
with different screening histories over the entire screening age range. It can therefore provide 
relevant indications about the expected impact of the adoption of these systems in an average risk 
population both at first and subsequent screening. The compliance with colonoscopy referral among 
subjects with positive screening test results and the colonoscopy completion rate were similar in the 
two groups: they were higher than the average level of these indicators in Italian programmes and 
consistent with the results of the regional programme in the more recent years. 16 The high quality 
of the assessment procedures reinforces the validity of our conclusions. 
In conclusion, our results would suggest that acceptability and diagnostic performance 
characteristics of the OC-Sensor and the newer HM-JACKarc systems are similar in a screening 
setting. The roll-out of programmes and the availability of endoscopy resources should be 
considered when choosing the f-Hb cut-off criterion for positivity of a FIT system for CRC 
screening. Selection of the same harmonised f-Hb  cut-off may still result in different PR and PPV 
for AN. Adopting f-Hb cut-offs to give equivalent PR allows instead for a direct comparison of the 
performance of different systems when using the same amount of endoscopy resources.  Using PR 
as a reference might also reduce the variation possibly related to ongoing technical developments of 
the specimen collection devices (of the buffer in particular) introduced by manufacturers. A recent 
study, for example, showed that a change in the formulation of the OC-Sensor device buffer, aimed 
at stabilising the Hb in the samples and reducing Hb degradation,  was associated with higher f-Hb 
for values below the threshold of 20 μg Hb/g faeces compared with the old buffer21.  Although the 
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difference in the PR observed in that study was not statistically significant, different buffer 
formulations, and other factors, might alter the relationship between Hb concentration and PR.   
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Table 1    Characteristics of participants  
by FIT system, gender, age and screening history 
 
 First screening OC-Sensor HM-JACKarc 
 Age  
(years) 
Men 
N 
(%) 
Women 
N 
(%) 
Total 
N 
(%)* 
Men 
N 
(%) 
Women 
N 
(%) 
Total 
N 
(%)* 
50-54 2084 2187 4271 2188 2123 4311 
  48.8 51.2 77.6 50.8 49.2 77.2 
55-59 586 590 1176 561 620 1181 
  49.8 50.2 33.3 47.5 52.5 32.5 
60-64 687 656 1343 657 679 1336 
  51.2 48.8 22.8 49.2 50.8 22.7 
65-69 1026 1075 2101 1052 1009 2061 
  48.8 51.2 36.6 51.0 49.0 35.6 
70-74 416 441 857 399 463 862 
  48.5 51.5 23.5 46.3 53.7 23.4 
Total 4799 4949 9748 4857 4894 9751 
  49.2 50.8 40.1 49.8 50.2 39.7 
Subsequent 
screening OC-Sensor HM-JACKarc 
 Age (years) 
Men 
N 
(%) 
Women 
N 
(%) 
Total 
N 
(%)** 
Men 
N 
(%) 
Women 
N 
(%) 
Total 
N 
(%)** 
50-54 541 695 1236 577 697 1274 
  43.8 56.2 22.4 45.3 54.7 22.8 
55-59 1052 1300 2352 1078 1376 2454 
  44.7 55.3 66.7 43.9 56.1 67.5 
60-64 2045 2512 4557 1994 2547 4541 
  44.9 55.1 77.2 43.9 56.1 77.3 
65-69 1625 2007 3632 1712 2021 3733 
  44.7 55.3 63.4 45.9 54.1 64.4 
70-74 1257 1532 2789 1303 1518 2821 
  45.1 54.9 76.5 46.2 53.8 76.6 
Total 6520 8046 14566 6664 8159 14823 
  44.8 55.2 59.9 45.0 55.0 60.3 
Total  OC-Sensor HM-JACKarc 
 Age  
(years) 
Men 
N 
(%) 
Women 
N 
(%) 
Total 
N 
(%) 
Men 
N 
(%) 
Women 
N 
(%) 
Total 
N 
(%) 
50-54 2625 2882 5507 2765 2820 5585 
  47.7 52.3 22.6 49.5 50.5 22.7 
55-59 1638 1890 3528 1639 1996 3635 
  46.4 53.6 14.5 45.1 54.9 14.8 
60-64 2732 3168 5900 2651 3226 5877 
  46.3 53.7 24.3 45.1 54.9 23.9 
65-69 2651 3082 5733 2764 3030 5794 
  46.2 53.8 23.6 47.7 52.3 23.6 
70-74 1673 1973 3646 1702 1981 3683 
  45.9 54.1 15.0 46.2 53.8 15.0 
Total 11319 12995 24314 11521 13053 24574 
  46.6 53.4  46.9 53.1  
* percentage of subjects in the first screening round out of those in the age group 
** percentage of subjects in the subsequent screening rounds out of those in the age group 
 
& Distribution of N of previous tests: OC-Sensor: 1=17.0%; 2=28.9%; 3=26.3%; 4=26.3%; 5=1.5% 
            HM-JACKarc: 1=17.1%; 2=29.1%; 3=26.4%; 4=26.2%; 5=1.2%
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Table 2.     Uptake of the screening invitation with the OC-Sensor and HM-JACKarc systems  
by gender, age and screening history 
 
OC-Sensor – first screening 
 Men Women Total 
Age (years) Invited 
Uptake 
Invited 
Uptake 
Invited 
Uptake 
 
N % N % N % 
50-54 2084 560 26.9 2187 808 36.9 4271 1368 32.0 
55-59 586 97 16.6 590 99 16.8 1176 196 16.7 
60-64 687 101 14.7 656 76 11.6 1343 177 13.2 
65-69 1026 133 13.0 1075 124 11.5 2101 257 12.2 
70-74 416 69 16.6 441 71 16.1 857 140 16.3 
Total 4799 960 20.0 4949 1178 23.8 9748 2138 21.9 
HM-JACKarc – first screeing 
 Men Women Total 
Age (years) Invited 
Uptake 
Invited 
Uptake 
Invited 
Uptake 
N % N % N % 
50-54 2188 659 30.1 2123 771 36.3 4311 1430 33.2 
55-59 561 91 16.2 620 88 14.2 1181 179 15.2 
60-64 657 75 11.4 679 114 16.8 1336 189 14.1 
65-69 1052 101 9.6 1009 109 10.8 2061 210 10.2 
70-74 399 49 12.3 463 52 11.2 862 101 11.7 
Total 4857 975 20.1 4894 1134 23.2 9751 2109 21.6 
OC-Sensor – subsequent screening 
 Men Women Total 
Age (years) Invited 
Uptake 
Invited 
Uptake 
Invited 
Uptake 
N % N % N % 
50-54 541 440 81.3 695 575 82.7 1236 1015 82.1 
55-59 1052 860 81.7 1300 1050 80.8 2352 1910 81.2 
60-64 2045 1844 90.2 2512 2198 87.5 4557 4042 88.7 
65-69 1625 1452 89.4 2007 1703 84.9 3632 3155 86.9 
70-74 1257 1091 86.8 1532 1231 80.4 2789 2322 83.3 
Total * 6520 5687 87.2 8046 6757 84.0 14566 12444 85.4 
HM-JACKarc – subsequent screening 
 Men Women Total 
Age (years) Invited 
Uptake 
Invited 
Uptake 
Invited 
Uptake 
N % N % N % 
50-54 577 457 79.2 697 565 81.1 1274 1022 80.2 
55-59 1078 876 81.3 1376 1102 80.1 2454 1978 80.6 
60-64 1994 1692 84.9 2547 2162 84.9 4541 3854 84.9 
65-69 1712 1467 85.7 2021 1687 83.5 3733 3154 84.5 
70-74 1303 1109 85.1 1518 1190 78.4 2821 2299 81.5 
Total * 6664 5601 84.0 8159 6706 82.2 14823 12307 83.0 
 
* RR - OC-Sensor vs HM-JACKarc: 1.03 (95%CI: 1.02-1.04).
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Table 3:   Positivity and colonoscopy performed and completed  
for OC-Sensor and HM-JACKarc systems  by gender, age and screening history 
OC-Sensor – Men - first screening 
Age (years) Examined FIT positive Colonoscopy performed Colonoscopy completed 
  N % N % N % 
50-54 560 30 5.4 28 93.3 26 92.9 
55-59 97 8 8.2 6 75.0 5 83.3 
60-64 101 9 8.9 7 77.8 7 100.0 
65-69 133 13 9.8 9 69.2 9 100.0 
70-74 69 14 20.3 13 92.9 12 92.3 
Total 960 74 7.7 63 85.1 59 93.7 
 OC-Sensor – Women - first screening 
Age (years) Examined 
FIT positive Colonoscopy performed Colonoscopy completed 
N % N % N % 
50-54 808 30 3.7 28 93.3 25 89.3 
55-59 99 3 3.0 3 100.0 3 100.0 
60-64 76 5 6.6 4 80.0 4 100.0 
65-69 124 9 7.3 4 44.4 2 50.0 
70-74 71 19 26.8 14 73.7 13 92.9 
Total 1178 66 5.6 53 80.3 47 88.7 
 OC-Sensor – Total - first screening 
Age (years) Examined 
FIT positive* Colonoscopy performed * Colonoscopy completed * 
N % N % N % 
50-54 1368 60 4.4 56 93.3 51 91.1 
55-59 196 11 5.6 9 81.8 8 88.9 
60-64 177 14 7.9 11 78.6 11 100.0 
65-69 257 22 8.6 13 59.1 11 84.6 
70-74 140 33 23.6 27 81.8 25 92.6 
Total 2138 140 6.5 116 82.9 106 91.4 
 HM-JACKarc – Men - first screening 
Age (years) Examined 
FIT positive Colonoscopy performed Colonoscopy completed 
N % N % N % 
50-54 659 25 3.8 24 96.0 24 100.0 
55-59 91 6 6.6 4 66.7 4 100.0 
60-64 75 7 9.3 7 100.0 7 100.0 
65-69 101 11 10.9 8 72.7 7 87.5 
70-74 49 30 61.2 27 90.0 27 100.0 
Total 975 79 8.1 70 88.6 69 98.6 
 HM-JACKarc – Women - first screening 
Age (years) Examined 
FIT positive Colonoscopy performed Colonosocpy completed 
N % N % N % 
50-54 771 21 2.7 18 85.7 17 94.4 
55-59 88 1 1.1 1 100.0 1 100.0 
60-64 114 9 7.9 8 88.9 7 87.5 
65-69 109 9 8.3 8 88.9 7 87.5 
70-74 52 12 23.1 12 100.0 11 91.7 
Total 1134 52 4.6 47 90.4 43 91.5 
 HM-JACKarc  - Total – first screening 
Age (years) Examined 
FIT positive * Colonoscopy performed * Colonoscopy completed * 
N % N % N % 
50-54 1430 46 3.2 42 91.3 41 97.6 
55-59 179 7 3.9 5 71.4 5 100.0 
60-64 189 16 8.5 15 93.8 14 93.3 
65-69 210 20 9.5 16 80.0 14 87.5 
70-74 101 42 41.6 39 92.9 38 97.4 
Total 2109 131 6.2 117 89.3 112 95.7 
 
             * p (OC-Sensor vs HM-JACKarc ) = NS 
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  OC-Sensor – Men – subsequent screening 
Age 
(years) 
Examined 
FIT positive Colonoscopy performed Colonoscopy completed 
N  N  N  
50-54 440 23 5.2 20 87.0 20 100.0 
55-59 860 39 4.5 35 89.7 34 97.1 
60-64 1844 102 5.5 93 91.2 88 94.6 
65-69 1452 95 6.5 81 85.3 77 95.1 
70-74 1091 100 9.2 79 79.0 75 94.9 
Total 5687 359 6.3 308 85.8 294 95.5 
  OC-Sensor – Women  – subsequent screening 
Age 
(years) 
Examined 
FIT positive Colonoscopy performed Colonoscopy completed 
N  N  N  
50-54 575 25 4.3 21 84.0 19 90.5 
55-59 1050 40 3.8 28 70.0 28 100.0 
60-64 2198 86 3.9 77 89.5 73 94.8 
65-69 1703 101 5.9 85 84.2 81 95.3 
70-74 1231 82 6.7 66 80.5 63 95.5 
Total 6757 334 4.9 277 82.9 264 95.3 
  OC-Sensor – Total -– subsequent screening 
Age 
(years) 
Examined 
FIT positive ** Colonoscopy performed * Colonoscopy  completed * 
N  N  N  
50-54 1015 48 4.7 41 85.4 39 95.1 
55-59 1910 79 4.1 63 79.7 62 98.4 
60-64 4042 188 4.7 170 90.4 161 94.7 
65-69 3155 196 6.2 166 84.7 158 95.2 
70-74 2322 182 7.8 145 79.7 138 95.2 
Total 12444 693 5.6 585 84.4 558 95.4 
  HM-JACKarc – Men  – subsequent screening 
Age 
(years) 
Examined FIT positive Colonoscopy performed Colonoscopy completed 
  N  N  N  
50-54 457 16 3.5 8 50.0 8 100.0 
55-59 876 37 4.2 34 91.9 33 97.1 
60-64 1692 74 4.4 64 86.5 63 98.4 
65-69 1467 85 5.8 72 84.7 71 98.6 
70-74 1109 75 6.8 57 76.0 56 98.2 
Total 5601 287 5.1 235 81.9 231 98.3 
  HM-JACKarc- Women -– subsequent screening 
Age (years 
Examined FIT + Colonoscopy performed Colonoscopy completed 
  N  N  N  
50-54 565 16 2.8 14 87.5 14 100.0 
55-59 1102 34 3.1 28 82.4 27 96.4 
60-64 2162 73 3.4 64 87.7 61 95.3 
65-69 1687 64 3.8 57 89.1 55 96.5 
70-74 1190 73 6.1 53 72.6 52 98.1 
Total 6706 260 3.9 216 83.1 209 96.8 
 HM-JACKarc – Total – subsequent screening 
Age 
(years) 
Examined 
FIT positive ** Colonoscopy performed * Colonoscopy  completed * 
N  N  N  
50-54 1022 32 3.1 22 68.8 22 100.0 
55-59 1978 71 3.6 62 87.3 60 96.8 
60-64 3854 147 3.8 128 87.1 124 96.9 
65-69 3154 149 4.7 129 86.6 126 97.7 
70-74 2299 148 6.4 110 74.3 108 98.2 
Total 12307 547 4.4 451 82.4 440 97.6 
 
               * p (OC-Sensor vs HM-JACKarc ) = NS 
** RR - OC-Sensor vs HM-JACKarc: 1.25 (95%CI: 1.12-1.40). 
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Table 4.              Detection rate and positive predictive value (PPV) for advanced adenoma and CRC 
                                               by gender, age and screening history 
OC-Sensor - Men - first screening 
Age (years) FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 5.4 28 6 1.1 0 0.00 21.4 
55-59 8.2 6 2 2.1 0 0.00 33.3 
60-64 8.9 7 4 4.0 0 0.00 57.1 
65-69 9.8 9 2 1.5 1 0.75 33.3 
70-74 20.3 13 3 4.4 1 1.45 30.8 
Total 7.7 63 17 1.8 2 0.21 30.2 
OC-Sensor - Women - first screening 
Age (years) FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 3.7 28 6 0.74 0 0.00 21.4 
55-59 3.0 3 0 0.00 0 0.00 0.0 
60-64 6.6 4 0 0.00 1 1.32 25.0 
65-69 7.3 4 0 0.00 1 0.81 25.0 
70-74 26.8 14 2 2.82 1 1.41 21.4 
Total 5.6 53 8 0.68 3 0.25 20.8 
OC-Sensor - Total - first screening 
Age (years) FIT positive Colonoscopy Advanced adenoma CRC * PPV AN * 
N N N % N % N 
50-54 4.4 56 12 0.88 0 0.00 21.4 
55-59 5.6 9 2 1.02 0 0.00 22.2 
60-64 7.9 11 4 2.26 1 0.56 45.5 
65-69 8.6 13 2 0.78 2 0.78 30.8 
70-74 23.6 27 5 3.57 2 1.43 25.9 
Total 6.5 116 25 1.17 5 0.23 25.9 
HM-JACKarc - Men - first screening 
Age (years) 
FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 3.8 24 4 0.61 2 0.30 25.0 
55-59 6.6 4 1 1.10 0 0.00 25.0 
60-64 9.3 7 0 0.00 0 0.00 0.0 
65-69 10.9 8 5 4.95 0 0.00 62.5 
70-74 61.2 27 7 14.29 1 2.04 29.6 
Total 8.1 70 17 1.74 3 0.31 28.6 
HM-JACKarc - Women - first screening 
Age (years) 
FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 2.7 18 4 0.52 2 0.26 33.3 
55-59 1.1 1 0 0.00 0 0.00 0.0 
60-64 7.9 8 2 1.75 0 0.00 25.0 
65-69 8.3 8 1 0.92 0 0.00 12.5 
70-74 23.1 12 1 1.92 0 0.00 8.3 
Total 4.6 47 8 0.71 2 0.18 21.3 
HM-JACKarc - Total- first screening- 
Age (years) 
FIT positive Colonoscopy Advanced adenoma CRC * PPV AN * 
N N N % N % % 
50-54 3.2 42 8 0. 6 4 0.28 28.6 
55-59 3.9 5 1 0. 6 0 0.00 20.0 
60-64 8.5 15 2 1.1 0 0.00 13.3 
65-69 9.5 16 6 2.9 0 0.00 37.5 
70-74 41.6 39 8 7.9 1 0.99 23.1 
Total 6.2 117 25 1.2 5 0.24 25.6 
 
* p (OC-Sensor vs HM-JACKarc ) = NS 
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OC-Sensor - Men - subsequent screening 
Age (years) 
FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 5.2 20 3 0.7 0 0.00 15.0 
55-59 4.5 35 3 0.4 0 0.00 8.6 
60-64 5.5 93 16 0.89 2 0.11 19.4 
65-69 6.5 81 17 1.2 3 0.21 24.7 
70-74 9.2 79 17 1.6 2 0.18 24.1 
Total 6.3 308 56 1.0 7 0.12 20.5 
OC-Sensor - Women - subsequent screening 
Age (years) 
FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 4.3 21 3 0.5 1 0.17 19.1 
55-59 3.8 28 3 0.3 0 0.00 10.7 
60-64 3.9 77 16 0.7 3 0.14 24.7 
65-69 5.9 85 13 0.8 2 0.12 17.7 
70-74 6.7 66 14 1.1 1 0.08 22.7 
Total 4.9 277 49 0.7 7 0.10 20.2 
OC-Sensor - Total - subsequent screening 
Age (years) 
FIT positive Colonoscopy Advanced adenoma * CRC * PPV AN * 
N N N % N % N 
50-54 4.7 41 6 0.6 1 0.10 17.1 
55-59 4.1 63 6 0.3 0 0.00 9.5 
60-64 4.7 170 32 0.8 5 0.12 21.8 
65-69 6.2 166 30 1.0 5 0.16 21.1 
70-74 7.8 145 31 1.3 3 0.13 23.4 
Total 5.6 585 105 0.8 14 0.11 20.3 
HM-JACKarc - Men - subsequent screening 
Age (years) 
FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 3.5 8 4 0.9 0 0.00 50.0 
55-59 4.2 34 10 1.1 0 0.00 29.4 
60-64 4.4 64 19 1.1 1 0.06 31.3 
65-69 5.8 72 15 1.0 2 0.14 23.6 
70-74 6.8 57 11 1.0 0 0.00 19.3 
Total 5.1 235 59 1.1 3 0.05 26.4 
HM-JACKarc - Women - subsequent screening 
Age (years) FIT positive Colonoscopy Advanced adenoma CRC PPV AN 
N N N % N % N 
50-54 2.8 14 1 0.2 0 0.00 7.1 
55-59 3.1 28 5 0.5 1 0.09 21.4 
60-64 3.4 64 9 0.4 3 0.14 18.8 
65-69 3.8 57 4 0.2 4 0.24 14.0 
70-74 6.1 53 8 0.7 5 0.42 24.5 
Total 3.9 216 27 0.4 13 0.19 18.5 
HM-JACKarc - Total- subsequent screening 
Age (years) FIT positive Colonoscopy Advanced adenoma * CRC * PPV AN * 
N N N % N % N 
50-54 3.1 22 5 0.5 0 0.00 22.7 
55-59 3.6 62 15 0.8 1 0.05 25.8 
60-64 3.8 128 28 0.7 4 0.10 25.0 
65-69 4.7 129 19 0.6 6 0.19 19.4 
70-74 6.4 110 19 0.8 5 0.22 21.8 
Total 4.4 451 86 0.7 16 0.13 22.6 
 
* p (OC-Sensor vs HM-JACKarc ) = NS 
PPV=positive predictive value; AN=advanced neoplasia – CRC+advanced adenoma 
